Celcuity Stock (NASDAQ:CELC)


ForecastRevenueOwnershipFinancialsChartTranscripts

Previous Close

$15.50

52W Range

$9.99 - $22.19

50D Avg

$15.43

200D Avg

$16.40

Market Cap

$552.86M

Avg Vol (3M)

$282.98K

Beta

0.75

Div Yield

-

CELC Company Profile


Celcuity Inc., a clinical stage biotechnology company, focuses on the development of molecularly targeted therapies for cancer patients in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment. Its drug candidate includes Gedatolisib, which selectively targets various class I isoforms of PI3K and mammalian target of rapamycin and focus on the treatment of patients with hormone receptor positive, HER2-negative, and advanced or metastatic breast cancer. The company is also developing CELsignia MP test, a qualitative laboratory developed test that measures HER2, c-Met, and PI3K signaling activity in breast and ovarian tumor cells. It had a license agreement with Pfizer, Inc. for the development and commercialization rights to Gedatolisib. Celcuity Inc. was founded in 2011 and is headquartered in Minneapolis, Minnesota.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

55

IPO Date

Sep 20, 2017

Website

CELC Performance


CELC Financial Summary


Dec 23Dec 22Dec 21
Revenue---
Operating Income$-66.23M$-39.39M$-28.36M
Net Income$-63.78M$-41.35M$-30.56M
EBITDA$-66.09M$-38.26M$-28.34M
Basic EPS$-2.69$-2.68$-2.28
Diluted EPS$-2.69$-2.68$-2.28

Fiscal year ends in Dec 23 | Currency in USD

Latest Earnings Call Transcripts


Q2 24Aug 16, 24 | 3:50 PM
Q1 24May 15, 24 | 12:00 AM
Q4 23Mar 27, 24 | 6:40 PM

Peer Comparison


TickerCompany
ANABAnaptysBio, Inc.
CYTCyteir Therapeutics, Inc.
DBTXDecibel Therapeutics, Inc.
IKNAIkena Oncology, Inc.
MLYSMineralys Therapeutics, Inc.
EWTXEdgewise Therapeutics, Inc.
AVTEAerovate Therapeutics, Inc.
ACRVAcrivon Therapeutics, Inc. Common Stock
CSBRChampions Oncology, Inc.
ANTXAN2 Therapeutics, Inc.
CCCCC4 Therapeutics, Inc.
MNOVMediciNova, Inc.
RZLTRezolute, Inc.
HOWLWerewolf Therapeutics, Inc.
ANEBAnebulo Pharmaceuticals, Inc.
ADAGAdagene Inc.
MOLNMolecular Partners AG